NCT00353938 - Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 13, 2006

Primary Completion Date

September 2, 2009

Study Completion Date

January 10, 2011

Conditions

Posttraumatic Stress Disorder

Interventions

DRUG

3,4-methylenedioxymethamphetamine (125 mg)

Participants will receive an initial dose of 125 mg MDMA orally and, if investigator and participant deem appropriate, 2.5 hours later they will receive 62.5 mg MDMA orally.

DRUG

3,4-methyelendioxymethamphetamine (25 mg)

Participants will receive a 25 mg MDMA orally, and if investigator and participant agree, 2.5 hours later they will receive 12.5 mg MDMA orally.

BEHAVIORAL

Therapy

Non-directive therapy performed by a team of two co-therapists

Trial Locations (1)

Unknown

Offices of Peter Oehen MD, Biberist